TY - JOUR
T1 - Report of the Fifteenth International Symposium of the Foundation for Promotion of Cancer Research
T2 - New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features
AU - Multani, Pratik S.
AU - Tobinai, Kensei
AU - Kakizoe, Tadao
AU - Armitage, James O.
AU - Ohno, Ryuzo
AU - Sugimura, Takashi
N1 - Funding Information:
The members of the organizing committee greatly appreciate the contributions of all the speakers and participants at this international symposium and their contribution to its ultimate success. This symposium was supported by the Foundation for Promotion of Cancer Research to promote the program of the Second Term Comprehensive 10 Year Strategy for Cancer Control by the Ministry of Health, Labor and Welfare, Japan.
PY - 2002/9/1
Y1 - 2002/9/1
N2 - The Fifteenth International Symposium of the Foundation for Promotion of Cancer Research entitled 'New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features' was held in Tokyo on January 15-17, 2002. Twenty-nine invited speakers, including 12 from abroad and 17 from Japan, presented the updated results of their research. After an overview of the classification of hematological malignancies, new findings on some disease entities based on novel immunophenotypic and molecular genetic features were presented. The results of gene expression profiling and BCL6 and C-MYC gene rearrangement in diffuse large B-cell lymphoma were presented and oncogenic mechanism of acute myeloid leukemia was discussed. In the treatment of non-Hodgkin's lymphoma and acute leukemia, the present consensus and future directions were discussed based on the results of multicenter trials in the USA and Japan. As a molecular targeting therapy, the remarkable effect of a BCR-ABL tyrosine kinase inhibitor, STI571, in chronic myeloid leukemia and gastrointestinal stromal tumor was presented. Thereafter, promising results of active immunotherapy, chimeric anti-CD20 monoclonal antibody, anti-CD20 radioimmunoconjugate and anti-CD22 immunotoxin for B-cell lymphoma were presented. Finally, recent advances in allogeneic hematopoietic stem cell transplantation were discussed, focusing on reduced-intensity preparative regimens. The recent advances in basic and clinical research on hematological malignancies would lead to further improvement in the prognosis and quality of life of patients suffering from leukemia or lymphoma.
AB - The Fifteenth International Symposium of the Foundation for Promotion of Cancer Research entitled 'New Horizons in the Diagnosis and Treatment of Hematological Malignancies Based on Molecular Genetic Features' was held in Tokyo on January 15-17, 2002. Twenty-nine invited speakers, including 12 from abroad and 17 from Japan, presented the updated results of their research. After an overview of the classification of hematological malignancies, new findings on some disease entities based on novel immunophenotypic and molecular genetic features were presented. The results of gene expression profiling and BCL6 and C-MYC gene rearrangement in diffuse large B-cell lymphoma were presented and oncogenic mechanism of acute myeloid leukemia was discussed. In the treatment of non-Hodgkin's lymphoma and acute leukemia, the present consensus and future directions were discussed based on the results of multicenter trials in the USA and Japan. As a molecular targeting therapy, the remarkable effect of a BCR-ABL tyrosine kinase inhibitor, STI571, in chronic myeloid leukemia and gastrointestinal stromal tumor was presented. Thereafter, promising results of active immunotherapy, chimeric anti-CD20 monoclonal antibody, anti-CD20 radioimmunoconjugate and anti-CD22 immunotoxin for B-cell lymphoma were presented. Finally, recent advances in allogeneic hematopoietic stem cell transplantation were discussed, focusing on reduced-intensity preparative regimens. The recent advances in basic and clinical research on hematological malignancies would lead to further improvement in the prognosis and quality of life of patients suffering from leukemia or lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=0036725811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036725811&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyf080
DO - 10.1093/jjco/hyf080
M3 - Article
C2 - 12417606
AN - SCOPUS:0036725811
SN - 0368-2811
VL - 32
SP - 371
EP - 385
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 9
ER -